Racial and ethnic diversity in Janus kinase inhibitor alopecia areata clinical trials

Alopecia areata (AA) is a chronic autoimmune disease that causes non-scarring alopecia. In June 2022, baricitinib, a Janus kinase (JAK) inhibitor, became the first Federal Drug Administration (FDA) approved medication for adult patients with severe AA. This study aimed to analyze published JAK inhibitor alopecia areata randomized controlled trials to characterize and assess the racial and ethnic representation of participants. Attached below is a document listing the clinical trials assessed in our study.